Dennis Slamon, M.D., Ph.D.

A Short Biography:

Dennis J. Slamon, M.D., Ph.D., serves as director of Clinical/Translational Research, and as director of the Revlon/UCLA Women's Cancer Research Program at JCCC. He is a professor of medicine, chief of the Division of Hematology/Oncology and executive vice chair for research for UCLA's Department of Medicine. Slamon also serves as director of the medical advisory board for the National Colorectal Cancer Research Alliance, a fund-raising organization that promotes advances in colorectal cancer. For 12 years, Dr. Slamon and his colleagues conducted the laboratory and clinical research that led to the development of the new breast cancer drug Herceptin, which targets a specific genetic alteration found in about 25 percent of breast cancer patients. To acknowledge Slamon's accomplishments, President Clinton appointed Slamon to the three-member President's Cancer Panel in June 2000. A 1975 honors graduate of the University of Chicago's Pritzker School of Medicine, Slamon earned his Ph.D. in cell biology that same year. He completed his internship and residency at the University of Chicago Hospitals and Clinics, becoming chief resident in 1978. One year later, he became a fellow in the Division of Hematology/Oncology at UCLA.

Work Titles
CTSI Member, Internal Advisory Board Member, CTSI
UCLA Chief, Hematology-Oncology Chief, Oncology Treatment Center at UCLA Vice-Chair, Research, Professor, Medicine Member, Dumont-UCLA Liver Cancer Center Member, JCCC Signal Transduction and Therapeutics Program Area
Education:
Degrees:
M.D., Pritzker School of Medicine, University of Chicago, Chicago, IL, 1970 - 1975
Ph.D., University of Chicago, 1970 - 1975
B.S., Washington and Jefferson College, Washingotn, Pennsylvania, 1970
Fellowship:
1979 - 1981 UCLA School of Medicine
Internship:
1975 - 1976 University of Chicago Hospitals
Residency:
1976 - 1978 University of Chicago Hospitals
Certifications:
Certifications:
1981 American Board of Internal Medicine
1978 American Board of Internal Medicine

Contact Information:

Work Phone Number:

(310) 825-5193

(888) ONC-UCLA

Work Address:

700 Tiverton Ave
11-934 Factor
CAMPUS - 167817
Los Angeles, CA 90095


Detailed Biography:

Dennis J. Slamon, M.D., Ph.D., serves as director of Clinical/Translational Research, and as director of the Revlon/UCLA Women's Cancer Research Program at JCCC. He is a professor of medicine, chief of the Division of Hematology/Oncology and executive vice chair for research for UCLA's Department of Medicine. Slamon also serves as director of the medical advisory board for the National Colorectal Cancer Research Alliance, a fund-raising organization that promotes advances in colorectal cancer.

For 12 years, Slamon and his colleagues conducted the laboratory and clinical research that led to the development of the new breast cancer drug Herceptin, which targets a specific genetic alteration found in about 25 percent of breast cancer patients. To acknowledge Slamon's accomplishments, President Clinton appointed Slamon to the three-member President's Cancer Panel in June 2000.

Slamon has won nearly two dozen national research awards honoring his scientific endeavors. In 2000, Slamon was awarded the Translational Medicine Award by the USCD-Salk Institute as well as the Bristol-Myers Squibb Oncology Millennium Award for significant achievement and leadership in breast cancer research. In 2001, Slamon was awarded the Wadsworth Center's Brown-Hazen Award for Excellence in the Basic Sciences, and in 2002, he received the Jeffrey A. Gottlieb Memorial Award from the M.D. Anderson Cancer Center in Texas. In 2003, Slamon received the Dorothy P. Landon-AACR Prize for Translational Cancer Research, an international award given by the Kirk A. and Dorothy P. Landon Foundation and the American Association for Cancer Research. In 2004, the American Cancer Society presented Slamon with the Medal of Honor, the top award bestowed by the organization. In 2005, Kent State University in Ohio gave Slamon the Fifth Aultman Cancer Center Award and he also received the Distinguished Service Award from the Medical and Biological Sciences Alumni Association at the University of Chicago. That same year, he received the William McGuire Memorial Award at the San Antonio Breast Cancer Symposium.

In 2006, Slamon was honored with the American Society of Clinical Oncology's David A. Karnofsky Memorial Award and Lecture. Also in 2006, Slamon received the 18th Annual Donald Ware Waddell Award from Arizona Cancer Center; the European Institute of Oncology Breast Cancer Award; the 2nd Umberto Veronesi Award for the Future Fight Against Breast Cancer and the Lister Award for Translational Medicine from the University of Glasgow, Scotland. In 2007, Slamon received the 19th annual Warren Alpert Foundation Scientific Prize, awarded by Harvard Medical School. Also in 2007, he received the Friends of the National Library of Medicine Distinguished Medical Service Award and the Gairdner International Award, one of the most prestigious awards in biomedical science.

In 2008, Slamon received the Daniel Nathans Memorial Award from the Van Andel Research Institute and in 2009, he was awarded the Medical Science Award by the UCLA Medical Alumni and Aesculapians. Slamon has also received the Milken Family Medical Foundation Award in Cancer Research, the Upjohn Award in Internal Medicine and the Outstanding Young Investigator Award.

A 1975 honors graduate of the University of Chicago's Pritzker School of Medicine, Slamon earned his Ph.D. in cell biology that same year. He completed his internship and residency at the University of Chicago Hospitals and Clinics, becoming chief resident in 1978. One year later, he became a fellow in the Division of Hematology/Oncology at UCLA.

Publications:

A selected list of publications:

Johnston Stephen R D, Gómez Henry, Stemmer Salomon M, Richie Maria, Durante Michael, Pandite Lini, Goodman Vicki, Slamon Dennis   A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer Breast cancer research and treatment, 2013; 137(3): 755-66.
Konecny Gottfried E, Kolarova Teodora, O'Brien Neil A, Winterhoff Boris, Yang Guorong, Qi Jingwei, Qi Zhengdong, Venkatesan Natarajan, Ayala Raul, Luo Tong, Finn Richard S, Kristof Jessica, Galderisi Chad, Porta Diana Graus, Anderson Lee, Shi Michael M, Yovine Alejandro, Slamon Dennis J   Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells Molecular cancer therapeutics, 2013; 12(5): 632-42.
Fejzo Marlena S, Anderson Lee, von Euw Erika M, Kalous Ondrej, Avliyakulov Nuraly K, Haykinson Michael J, Konecny Gottfried E, Finn Richard S, Slamon Dennis J   Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer International journal of molecular sciences, 2013; 14(2): 3094-109.
Garon Edward B, Pietras Richard J, Finn Richard S, Kamranpour Naeimeh, Pitts Sharon, Márquez-Garbán Diana C, Desai Amrita J, Dering Judy, Hosmer Wylie, von Euw Erika M, Dubinett Steven M, Slamon Dennis J   Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013; 8(3): 270-8.
Perez Edith A, Press Michael F, Dueck Amylou C, Jenkins Robert B, Kim Chungyeul, Chen Beiyun, Villalobos Ivonne, Paik Soonmyung, Buyse Marc, Wiktor Anne E, Meyer Reid, Finnigan Melanie, Zujewski Joanne, Shing Mona, Stern Howard M, Lingle Wilma L, Reinholz Monica M, Slamon Dennis J   Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005) Breast cancer research and treatment, 2013; 138(1): 99-108.
Wainberg Zev A, Anghel Adrian, Rogers Amy M, Desai Amrita J, Kalous Ondrej, Conklin Dylan, Ayala Raul, O'Brien Neil A, Quadt Cornelia, Akimov Mikhail, Slamon Dennis J, Finn Richard S   Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer Molecular cancer therapeutics, 2013; 12(4): 509-19.
Finn Richard S, Aleshin Alexey, Dering Judy, Yang Peter, Ginther Charles, Desai Amrita, Zhao Danyun, von Euw Erika, Busuttil Ronald W, Slamon Dennis J   Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro Hepatology (Baltimore, Md.), 2013; 57(5): 1838-46.
Garon Edward B, Finn Richard S, Hamidi Habib, Dering Judy, Pitts Sharon, Kamranpour Naeimeh, Desai Amrita J, Hosmer Wylie, Ide Susan, Avsar Emin, Rugaard Jensen Michael, Quadt Cornelia, Liu Manway, Dubinett Steven M, Slamon Dennis J   The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth Molecular cancer therapeutics, 2013; 45(4): .
Hurvitz Sara A, Betting David J, Stern Howard M, Quinaux Emmanuel, Stinson Jeremy, Seshagiri Somasekar, Zhao Ying, Buyse Marc, Mackey John, Driga Adrian, Damaraju Sambasivarao, Sliwkowski Mark X, Robert Nicholas J, Valero Vicente, Crown John, Falkson Carla, Brufsky Adam, Pienkowski Tadeusz, Eiermann Wolfgang, Martin Miguel, Bee Valerie, Marathe Omkar, Slamon Dennis J, Timmerman John M   Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients Clinical cancer research : an official journal of the American Association for Cancer Research, 2012; 18(12): 3478-86.
Kalous Ondrej, Conklin Dylan, Desai Amrita J, O'Brien Neil A, Ginther Charles, Anderson Lee, Cohen David J, Britten Carolyn D, Taylor Ian, Christensen James G, Slamon Dennis J, Finn Richard S   Dacomitinib (PF-00299804), a irreversible pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib Molecular cancer therapeutics, 2012; .
Wu Yanyuan, Ginther Charles, Kim Juri, Mosher Nicole, Chung Seyung, Slamon Dennis, Vadgama Jaydutt V   Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells Molecular cancer research : MCR, 2012; 10(12): 1597-606.
Press Michael F, Gordon Michael A, Slamon Dennis J   Potential utility of an expression array signature for predicting anthracycline responsiveness or resistance Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012; 30(4): 357-61.
Logan Joshua E, Rampersaud Edward N, Sonn Geoffrey A, Chamie Karim, Belldegrun Arie S, Pantuck Allan J, Slamon Dennis J, Kabbinavar Fairooz F   Systemic therapy for metastatic renal cell carcinoma: a review and update Reviews in urology, 2012; 14(3-4): 65-78.
Fasching Peter A, Pharoah Paul D P, Cox Angela, Nevanlinna Heli, Bojesen Stig E, Karn Thomas, Broeks Annegien, van Leeuwen Flora E, van't Veer Laura J, Udo Renate, Dunning Alison M, Greco Dario, Aittomäki Kristiina, Blomqvist Carl, Shah Mitul, Nordestgaard Børge G, Flyger Henrik, Hopper John L, Southey Melissa C, Apicella Carmel, Garcia-Closas Montserrat, Sherman Mark, Lissowska Jolanta, Seynaeve Caroline, Huijts Petra E A, Tollenaar Rob A E M, Ziogas Argyrios, Ekici Arif B, Rauh Claudia, Mannermaa Arto, Kataja Vesa, Kosma Veli-Matti, Hartikainen Jaana M, Andrulis Irene L, Ozcelik Hilmi, Mulligan Anna-Marie, Glendon Gord, Hall Per, Czene Kamila, Liu Jianjun, Chang-Claude Jenny, Wang-Gohrke Shan, Eilber Ursula, Nickels Stefan, Dörk Thilo, Schiekel Maria, Bremer Michael, Park-Simon Tjoung-Won, Giles Graham G, Severi Gianluca, Baglietto Laura, Hooning Maartje J, Martens John W M, Jager Agnes, Kriege Mieke, Lindblom Annika, Margolin Sara, Couch Fergus J, Stevens Kristen N, Olson Janet E, Kosel Matthew, Cross Simon S, Balasubramanian Sabapathy P, Reed Malcolm W R, Miron Alexander, John Esther M, Winqvist Robert, Pylkäs Katri, Jukkola-Vuorinen Arja, Kauppila Saila, Burwinkel Barbara, Marme Frederik, Schneeweiss Andreas, Sohn Christof, Chenevix-Trench Georgia, Chenevix-Trench Georgia, Lambrechts Diether, Dieudonne Anne-Sophie, Hatse Sigrid, van Limbergen Erik, Benitez Javier, Milne Roger L, Zamora M Pilar, Pérez José Ignacio Arias, Bonanni Bernardo, Peissel Bernard, Loris Bernard, Peterlongo Paolo, Rajaraman Preetha, Schonfeld Sara J, Anton-Culver Hoda, Devilee Peter, Beckmann Matthias W, Slamon Dennis J, Phillips Kelly-Anne, Figueroa Jonine D, Humphreys Manjeet K, Easton Douglas F, Schmidt Marjanka K   The role of genetic breast cancer susceptibility variants as prognostic factors Human molecular genetics, 2012; 21(17): 3926-39.
Britten Carolyn D, Gomes Antoinette S, Wainberg Zev A, Elashoff David, Amado Rafael, Xin Yan, Busuttil Ronald W, Slamon Dennis J, Finn Richard S   Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study BMC cancer, 2012; 12(4): 16.
Slamon Dennis, Eiermann Wolfgang, Robert Nicholas, Pienkowski Tadeusz, Martin Miguel, Press Michael, Mackey John, Glaspy John, Chan Arlene, Pawlicki Marek, Pinter Tamas, Valero Vicente, Liu Mei-Ching, Sauter Guido, von Minckwitz Gunter, Visco Frances, Bee Valerie, Buyse Marc, Bendahmane Belguendouz, Tabah-Fisch Isabelle, Lindsay Mary-Ann, Riva Alessandro, Crown John, Crown John   Adjuvant trastuzumab in HER2-positive breast cancer The New England journal of medicine, 2011; 365(14): 1273-83.
Press Michael F, Sauter Guido, Buyse Marc, Bernstein Leslie, Guzman Roberta, Santiago Angela, Villalobos Ivonne E, Eiermann Wolfgang, Pienkowski Tadeusz, Martin Miguel, Robert Nicholas, Crown John, Bee Valerie, Taupin Henry, Flom Kerry J, Tabah-Fisch Isabelle, Pauletti Giovanni, Lindsay Mary-Ann, Riva Alessandro, Slamon Dennis J   Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011; 29(7): 859-67.
Tap William D, Eilber Fritz C, Ginther Charles, Dry Sarah M, Reese Nicholas, Barzan-Smith Kate, Chen Hsiao-Wang, Wu Hong, Eilber Frederick R, Slamon Dennis J, Anderson Lee   Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization Genes, chromosomes & cancer, 2011; 50(2): 95-112.
Konecny Gottfried E, Winterhoff Boris, Kolarova Teodora, Qi Jingwei, Manivong Kanthinh, Dering Judy, Yang Guorong, Chalukya Meenal, Wang He-Jing, Anderson Lee, Kalli Kimberly R, Finn Richard S, Ginther Charles, Jones Siân, Velculescu Victor E, Riehle Darren, Cliby William A, Randolph Sophia, Koehler Maria, Hartmann Lynn C, Slamon Dennis J   Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer Clinical cancer research : an official journal of the American Association for Cancer Research, 2011; 17(6): 1591-602.
Fejzo Marlena S, Ginther Chuck, Dering Judy, Anderson Lee, Venkatesan Natarajan, Konecny Gottfried, Karlan Beth, Slamon Dennis J   Knockdown of ovarian cancer amplification target ADRM1 leads to downregulation of GIPC1 and upregulation of RECK Genes, chromosomes & cancer, 2011; 50(6): 434-41.
Valero Vicente, Forbes John, Pegram Mark D, Pienkowski Tadeusz, Eiermann Wolfgang, von Minckwitz Gunter, Roche Henri, Martin Miguel, Crown John, Mackey John R, Fumoleau Pierre, Rolski Janusz, Mrsic-Krmpotic Zrinka, Jagiello-Gruszfeld Agnieszka, Riva Alessandro, Buyse Marc, Taupin Henry, Sauter Guido, Press Michael F, Slamon Dennis J   Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011; 29(2): 149-56.
Zhu Min, Saxton Romaine E, Ramos Lillian, Chang David D, Karlan Beth Y, Gasson Judith C, Slamon Dennis J   Neutralizing monoclonal antibody to periostin inhibits ovarian tumor growth and metastasis Molecular cancer therapeutics, 2011; 10(8): 1500-8.
Hurvitz Sara A, Allen Heather J, Moroose Rebecca L, Chan David, Hagenstad Christopher, Applebaum Steven H, Patel Giribala, Hu Eddie H, Ryba Nancy, Lin Lii-Shin, Wang Hejing, Glaspy John, Slamon Dennis J, Kabbinavar Fairooz   A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01) Clinical breast cancer, 2010; 10(4): 307-12.
O'Brien Neil A, Browne Brigid C, Chow Lucy, Wang Yuhua, Ginther Charles, Arboleda Jane, Duffy Michael J, Crown John, O'Donovan Norma, Slamon Dennis J   Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib Molecular cancer therapeutics, 2010; 9(6): 1489-502.
Konecny Gottfried E, Pauletti Giovanni, Untch Michael, Wang He-Jing, Möbus Volker, Kuhn Walther, Thomssen Christoph, Harbeck Nadia, Wang Ling, Apple Sophia, Jänicke Fritz, Slamon Dennis J   Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer Breast cancer research and treatment, 2010; 120(2): 481-9.
Wu Yanyuan, Alvarez Monica, Slamon Dennis J, Koeffler Phillip, Vadgama Jaydutt V   Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation BMC cancer, 2010; 10(5): 32.
Xu Jinhua, Huo Dezheng, Chen Yinghua, Nwachukwu Chika, Collins Cindy, Rowell Janelle, Slamon Dennis J, Olopade Olufunmilayo I   CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors Breast cancer research and treatment, 2010; 120(3): 593-601.
Wu Yanyuan, Shang Xiying, Sarkissyan Marianna, Slamon Dennis, Vadgama Jaydutt V   FOXO1A is a target for HER2-overexpressing breast tumors Cancer research, 2010; 70(13): 5475-85.
Jones Siân, Wang Tian-Li, Shih Ie-Ming, Mao Tsui-Lien, Nakayama Kentaro, Roden Richard, Glas Ruth, Slamon Dennis, Diaz Luis A, Vogelstein Bert, Kinzler Kenneth W, Velculescu Victor E, Papadopoulos Nickolas   Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma Science (New York, N.Y.), 2010; 330(6001): 228-31.
Garon Edward B, Finn Richard S, Hosmer Wylie, Dering Judy, Ginther Charles, Adhami Shahriar, Kamranpour Naeimeh, Pitts Sharon, Desai Amrita, Elashoff David, French Tim, Smith Paul, Slamon Dennis J   Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines Molecular cancer therapeutics, 2010; 9(7): 1985-94.
Wainberg Zev A, Anghel Adrian, Desai Amrita J, Ayala Raul, Luo Tong, Safran Brent, Fejzo Marlena S, Hecht J Randolph, Slamon Dennis J, Finn Richard S   Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo Clinical cancer research : an official journal of the American Association for Cancer Research, 2010; 16(5): 1509-19.
Zhu Min, Fejzo Marlena S, Anderson Lee, Dering Judy, Ginther Charles, Ramos Lillian, Gasson Judith C, Karlan Beth Y, Slamon Dennis J   Periostin promotes ovarian cancer angiogenesis and metastasis Gynecologic oncology, 2010; 119(2): 337-44.
Tap William D, Gong Ke-Wei, Dering Judy, Tseng Yiou, Ginther Charles, Pauletti Giovanni, Glaspy John A, Essner Richard, Bollag Gideon, Hirth Peter, Zhang Chao, Slamon Dennis J   Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma Neoplasia (New York, N.Y.), 2010; 12(8): 637-49.
Oh Juliana J, Taschereau Eileen O, Koegel Ashley K, Ginther Charles L, Rotow Julia K, Isfahani Khadijeh Z, Slamon Dennis J   RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasis Lung cancer (Amsterdam, Netherlands), 2010; 70(3): 253-62.
Fejzo Marlena Schoenberg, Slamon Dennis J   Tissue microarrays from frozen tissues-OCT technique Methods in molecular biology (Clifton, N.J.), 2010; 664(5): 73-80.
Britten Carolyn D, Finn Richard S, Bosserman Linda D, Wong Steven G, Press Michael F, Malik Mubashira, Lum Bert L, Slamon Dennis J   A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach Clinical breast cancer, 2009; 9(1): 16-22.
Slamon Dennis J, Press Michael F   Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers Journal of the National Cancer Institute, 2009; 101(9): 615-8.
Kuo Kuan-Ting, Mao Tsui-Lien, Jones Siân, Veras Emanuela, Ayhan Ayse, Wang Tian-Li, Glas Ruth, Slamon Dennis, Velculescu Victor E, Kuman Robert J, Shih Ie-Ming   Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma The American journal of pathology, 2009; 174(5): 1597-601.
Sauter Guido, Lee James, Bartlett John M S, Slamon Dennis J, Press Michael F   Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009; 27(8): 1323-33.
Finn Richard S, Dering Judy, Conklin Dylan, Kalous Ondrej, Cohen David J, Desai Amrita J, Ginther Charles, Atefi Mohammad, Chen Isan, Fowst Camilla, Los Gerret, Slamon Dennis J   PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro Breast cancer research : BCR, 2009; 11(5): R77.
Britten Carolyn D, Kabbinavar Fairooz, Hecht J Randolph, Bello Carlo L, Li Jim, Baum Charles, Slamon Dennis   A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period Cancer chemotherapy and pharmacology, 2008; 61(3): 515-24.
Wu Yanyuan, Mohamed Hezla, Chillar Ram, Ali Ishrat, Clayton Sheila, Slamon Dennis, Vadgama Jaydutt V   Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer Breast cancer research : BCR, 2008; 10(1): R3.
Fejzo Marlena S, Dering Judy, Ginther Chuck, Anderson Lee, Ramos Lilian, Walsh Christine, Karlan Beth, Slamon Dennis J   Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target Genes, chromosomes & cancer, 2008; 47(10): 873-83.
Walsh Christine S, Ogawa Seishi, Karahashi Hisae, Scoles Daniel R, Pavelka James C, Tran Hang, Miller Carl W, Kawamata Norihiko, Ginther Charles, Dering Judy, Sanada Masashi, Nannya Yasuhito, Slamon Dennis J, Koeffler H Phillip, Karlan Beth Y   ERCC5 is a novel biomarker of ovarian cancer prognosis Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008; 26(18): 2952-8.
Watanabe Masaru, Fiji Hannah D G, Guo Lea, Chan Lai, Kinderman Sape S, Slamon Dennis J, Kwon Ohyun, Tamanoi Fuyuhiko   Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds The Journal of biological chemistry, 2008; 283(15): 9571-9.
Oh Juliana J, Boctor Baher N, Jimenez Cynthia A, Lopez Roberto, Koegel Ashley K, Taschereau Eileen O, Phan Diana T, Jacobsen Steven E, Slamon Dennis J   Promoter methylation study of the H37/RBM5 tumor suppressor gene from the 3p21.3 human lung cancer tumor suppressor locus Human genetics, 2008; 123(1): 55-64.
Jones Lee W, Haykowsky Mark, Peddle Carolyn J, Joy Anil A, Pituskin Edith N, Tkachuk Linda M, Courneya Kerry S, Slamon Dennis J, Mackey John R   Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2007; 16(5): 1026-31.
Finn Richard S, Dering Judy, Ginther Charles, Wilson Cindy A, Glaspy Padraic, Tchekmedyian Nishan, Slamon Dennis J   Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro Breast cancer research and treatment, 2007; 105(3): 319-26.
Munster Pamela N, Britten Carolyn D, Mita Monica, Gelmon Karen, Minton Susan E, Moulder Stacy, Slamon Dennis J, Guo Feng, Letrent Stephen P, Denis Louis, Tolcher Anthony W   First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors Clinical cancer research : an official journal of the American Association for Cancer Research, 2007; 13(4): 1238-45.
Milstein Marc, Mooser Chelsea K, Hu Hailiang, Fejzo Marlena, Slamon Dennis, Goodglick Lee, Dry Sarah, Colicelli John   RIN1 is a breast tumor suppressor gene Cancer research, 2007; 67(24): 11510-6.
Hinestrosa M Carolina, Dickersin Kay, Klein Pamela, Mayer Musa, Noss Karin, Slamon Dennis, Sledge George, Visco Frances M   Shaping the future of biomarker research in breast cancer to ensure clinical relevance Nature reviews. Cancer, 2007; 7(4): 309-15.
Oh Juliana J, Koegel Ashley K, Phan Diana T, Razfar Ali, Slamon Dennis J   The two single nucleotide polymorphisms in the H37/RBM5 tumour suppressor gene at 3p21.3 correlated with different subtypes of non-small cell lung cancers Lung cancer (Amsterdam, Netherlands), 2007; 58(1): 7-14.
Oh Juliana J, Razfar Ali, Delgado Idolina, Reed Rebecca A, Malkina Anna, Boctor Baher, Slamon Dennis J   3p21.3 tumor suppressor gene H37/Luca15/RBM5 inhibits growth of human lung cancer cells through cell cycle arrest and apoptosis Cancer research, 2006; 66(7): 3419-27.
Konecny Gottfried E, Pegram Mark D, Venkatesan Natarajan, Finn Richard, Yang Guorong, Rahmeh Martina, Untch Michael, Rusnak David W, Spehar Glenn, Mullin Robert J, Keith Barry R, Gilmer Tona M, Berger Mark, Podratz Karl C, Slamon Dennis J   Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells Cancer research, 2006; 66(3): 1630-9.
Slamon Dennis J, Romond Edward H, Perez Edith A, Perez Edith A   Advances in adjuvant therapy for breast cancer Clinical advances in hematology & oncology : H&O, 2006; 4(3 Suppl 7): suppl 1, 4-9; discussion suppl 10; quiz 2 p following suppl 10.
Hurley Judith, Doliny Philomena, Reis Isildinha, Silva Orlando, Gomez-Fernandez Carmen, Velez Pedro, Pauletti Giovanni, Powell Jodeen E, Pegram Mark D, Slamon Dennis J   Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006; 24(12): 1831-8.
Robert Nicholas, Leyland-Jones Brian, Asmar Lina, Belt Robert, Ilegbodu Des, Loesch David, Raju Robert, Valentine Elizabeth, Sayre Robert, Cobleigh Melody, Albain Kathy, McCullough Cecelia, Fuchs Lea, Slamon Dennis   Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006; 24(18): 2786-92.
Esteva Francisco J, Cheli Carol D, Fritsche Herbert, Fornier Monica, Slamon Dennis, Thiel Robert P, Luftner Diana, Ghani Farooq   Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies Breast cancer research : BCR, 2005; 7(4): R436-43.
Press Michael F, Sauter Guido, Bernstein Leslie, Villalobos Ivonne E, Mirlacher Martina, Zhou Jian-Yuan, Wardeh Rooba, Li Yong-Tian, Guzman Roberta, Ma Yanling, Sullivan-Halley Jane, Santiago Angela, Park Jinha M, Riva Alessandro, Slamon Dennis J   Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials Clinical cancer research : an official journal of the American Association for Cancer Research, 2005; 11(18): 6598-607.
Mass Robert D, Press Michael F, Anderson Steven, Cobleigh Melody A, Vogel Charles L, Dybdal Noël, Leiberman Grazyna, Slamon Dennis J   Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab Clinical breast cancer, 2005; 6(3): 240-6.
Wilson Cindy A, Slamon Dennis J   Evolving understanding of growth regulation in human breast cancer: interactions of the steroid and peptide growth regulatory pathways Journal of the National Cancer Institute, 2005; 97(17): 1238-9.
Carlson Anne, Berkowitz Jeanne McAdara, Browning Damaris, Slamon Dennis J, Gasson Judith C, Yates Karen E   Expression of c-Fes protein isoforms correlates with differentiation in myeloid leukemias DNA and cell biology, 2005; 24(5): 311-6.
Wilson Cindy A, Cajulis Elaina E, Green Jennifer L, Olsen Taylor M, Chung Young Ah, Damore Michael A, Dering Judy, Calzone Frank J, Slamon Dennis J   HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells Breast cancer research : BCR, 2005; 7(6): R1058-79.
Carlson Anne, Yates Karen E, Slamon Dennis J, Gasson Judith C   Spatial and temporal changes in the subcellular localization of the nuclear protein-tyrosine kinase, c-Fes DNA and cell biology, 2005; 24(4): 225-34.
Byrne Jennifer A, Balleine Rosemary L, Schoenberg Fejzo Marlena, Mercieca Janelle, Chiew Yoke-Eng, Livnat Yael, St Heaps Luke, Peters Gregory B, Byth Karen, Karlan Beth Y, Slamon Dennis J, Harnett Paul, Defazio Anna   Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer International journal of cancer. Journal international du cancer, 2005; 117(6): 1049-54.
Oh Juliana J, Boctor Baher, Jimenez Cynthia A, Lopez Roberto C, Razfar Ali, Slamon Dennis J   Use of low-melting-point primers for bisulfite genomic sequencing: analysis of the H37 lung cancer tumor suppressor gene promoter Analytical biochemistry, 2005; 343(2): 347-9.
Konecny Gottfried E, Meng Y Gloria, Untch Michael, Wang He-Jing, Bauerfeind Ingo, Epstein Melinda, Stieber Petra, Vernes Jean-Michel, Gutierrez Johnny, Hong Kyu, Beryt Malgorzata, Hepp Hermann, Slamon Dennis J, Pegram Mark D   Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients Clinical cancer research : an official journal of the American Association for Cancer Research, 2004; 10(5): 1706-16.
Bryant Joshua A, Finn Richard S, Slamon Dennis J, Cloughesy Timothy F, Charles Andrew C   EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells Cancer biology & therapy, 2004; 3(12): 1243-9.
Oh Juliana J, Fishbein Michael C, Boctor Baher, Jimenez Cynthia A, Lopez Robert, Slamon Dennis J   Evaluation of H37, a candidate 3p21.3 tumor suppressor gene, as a therapeutic and diagnostic marker in lung cancer Chest, 2004; 125(5 Suppl): 102S-3S.
Konecny Gottfried E, Thomssen Christoph, Lück Hans Joachim, Untch Michael, Wang He-Jing, Kuhn Walter, Eidtmann Holger, du Bois Andreas, Olbricht Sigrid, Steinfeld Dieter, Möbus Volker, von Minckwitz Gunter, Dandekar Suganda, Ramos Lillian, Pauletti Giovanni, Pegram Mark D, Jänicke Fritz, Slamon Dennis J   Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer Journal of the National Cancer Institute, 2004; 96(15): 1141-51.
Pegram Mark D, Konecny Gottfried E, O'Callaghan Carminda, Beryt Malgorzata, Pietras Richard, Slamon Dennis J   Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer Journal of the National Cancer Institute, 2004; 96(10): 739-49.
Park John W, Kerbel Robert S, Kelloff Gary J, Barrett J Carl, Chabner Bruce A, Parkinson David R, Peck Jonathan, Ruddon Raymond W, Sigman Caroline C, Slamon Dennis J   Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development Clinical cancer research : an official journal of the American Association for Cancer Research, 2004; 10(11): 3885-96.
Pegram Mark D, Pienkowski Tadeusz, Northfelt Donald W, Eiermann Wolfgang, Patel Ravi, Fumoleau Pierre, Quan Eleonor, Crown John, Toppmeyer Deborah, Smylie Michael, Riva Alessandro, Blitz Sandra, Press Michael F, Reese David, Lindsay Mary-Ann, Slamon Dennis J   Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer Journal of the National Cancer Institute, 2004; 96(10): 759-69.
Tripathy Debu, Slamon Dennis J, Cobleigh Melody, Arnold Andrew, Saleh Mansoor, Mortimer Joanne E, Murphy Maureen, Stewart Stanford J   Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004; 22(6): 1063-70.
Slamon Dennis J   The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors The oncologist, 2004; 9 Suppl 3(5): 1-3.
Konecny Gottfried E, Wilson Cindy A, Slamon Dennis J   Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention? Journal of the National Cancer Institute, 2003; 95(24): 1813-5.
Finn Richard S, Slamon Dennis J   Monoclonal antibody therapy for breast cancer: herceptin Cancer chemotherapy and biological response modifiers, 2003; 21(2): 223-33.
Arboleda M Jane, Lyons John F, Kabbinavar Fairooz F, Bray Mark R, Snow Bryan E, Ayala Raul, Danino Mordechai, Karlan Beth Y, Slamon Dennis J   Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells Cancer research, 2003; 63(1): 196-206.
Konecny Gottfried, Pauletti Giovanni, Pegram Mark, Untch Michael, Dandekar Sugandha, Aguilar Zuleima, Wilson Cindy, Rong Hong-Mei, Bauerfeind Ingo, Felber Margret, Wang He-Jing, Beryt Malgorzata, Seshadri Ram, Hepp Herrmann, Slamon Dennis J   Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer Journal of the National Cancer Institute, 2003; 95(2): 142-53.
Oh Juliana J, West Alison R, Fishbein Michael C, Slamon Dennis J   A candidate tumor suppressor gene, H37, from the human lung cancer tumor suppressor locus 3p21.3 Cancer research, 2002; 62(11): 3207-13.
Elkas John C, Baldwin Rae Lynn, Pegram Mark, Tseng Yiou, Slamon Dennis, Karlan Beth Y   A human ovarian carcinoma murine xenograft model useful for preclinical trials Gynecologic oncology, 2002; 87(2): 200-6.
Buller Richard E, Runnebaum Ingo B, Karlan Beth Y, Horowitz Jo Ann, Shahin Mark, Buekers Thomas, Petrauskas Stan, Kreienberg Rolf, Slamon Dennis, Pegram Mark   A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer Cancer gene therapy, 2002; 9(7): 553-66.
Slamon Dennis   Biologic Approaches to Managing Advanced Breast Cancer Cancer control : journal of the Moffitt Cancer Center, 2002; 6(5 Suppl 2): 7-11.
Paquette Ronald L, Dergham Sanaa T, Karpf Ellen, Wang He-Jing, Slamon Dennis J, Souza Larry, Glaspy John A   Culture conditions affect the ability of ex vivo expanded peripheral blood progenitor cells to accelerate hematopoietic recovery Experimental hematology, 2002; 30(4): 374-80.
Namazie Ali, Alavi Sassan, Olopade Olufunmilayo I, Pauletti Giovanni, Aghamohammadi Neema, Aghamohammadi M, Gornbein Jeffrey A, Calcaterra Thomas C, Slamon Dennis J, Wang Marilene B, Srivatsan Eri S   Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors The Laryngoscope, 2002; 112(3): 472-81.
Osoba David, Slamon Dennis J, Burchmore Michael, Murphy Maureen   Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002; 20(14): 3106-13.
Vogel Charles L, Cobleigh Melody A, Tripathy Debu, Gutheil John C, Harris Lyndsay N, Fehrenbacher Louis, Slamon Dennis J, Murphy Maureen, Novotny William F, Burchmore Michael, Shak Steven, Stewart Stanford J, Press Michael   Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002; 20(3): 719-26.
Press Michael F, Slamon Dennis J, Flom Kerry J, Park Jinha, Zhou Jian-Yuan, Bernstein Leslie   Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002; 20(14): 3095-105.
Konecny Gottfried, Slamon Dennis J   HER2 testing and correlation with efficacy of trastuzumab therapy Oncology (Williston Park, N.Y.), 2002; 16(11): 1576, 1578.
Buller Richard E, Shahin Mark S, Horowitz Jo Ann, Runnebaum Ingo B, Mahavni Vikas, Petrauskas Stan, Kreienberg Rolf, Karlan Beth, Slamon Dennis, Pegram Mark   Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500 Cancer gene therapy, 2002; 9(7): 567-72.
Shawver Laura K, Slamon Dennis, Ullrich Axel   Smart drugs: tyrosine kinase inhibitors in cancer therapy Cancer cell, 2002; 1(2): 117-23.

Does this profile need updating? Contact Us